Trial Outcomes & Findings for Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation (NCT NCT03755414)

NCT ID: NCT03755414

Last Updated: 2025-04-06

Results Overview

Failure to engraft will be defined as failure to achieve absolute neutrophil count \>500 for 3 days by day 35.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

55 participants

Primary outcome timeframe

By day 35

Results posted on

2025-04-06

Participant Flow

Participant milestones

Participant milestones
Measure	Pilot Study: Itacitinib * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently * To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure.	Expansion Phase: Itacitinib * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently	Donors -Donors were consented for the patients enrolled in the Safety Lead-In Phase (planned 3 patients). Donors were consented for a second CD34+ collection to use as a rescue in the case of engraftment failure and for collection of a research blood specimen prior to mobilization.
Overall Study STARTED	22	27	6
Overall Study COMPLETED	20	25	4
Overall Study NOT COMPLETED	2	2	2

Reasons for withdrawal

Reasons for withdrawal
Measure	Pilot Study: Itacitinib * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently * To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure.	Expansion Phase: Itacitinib * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently	Donors -Donors were consented for the patients enrolled in the Safety Lead-In Phase (planned 3 patients). Donors were consented for a second CD34+ collection to use as a rescue in the case of engraftment failure and for collection of a research blood specimen prior to mobilization.
Overall Study Did not continue with treatment due to low donor collection	2	1	0
Overall Study Recipient did not continue with treatment due to low donor cell collection	0	0	2
Overall Study Non-compliance	0	1	0

Baseline Characteristics

Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Pilot Study: Itacitinib n=22 Participants * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently * To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure.	Expansion Phase: Itacitinib n=27 Participants * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently	Donors n=6 Participants -Donors were consented for the patients enrolled in the Safety Lead-In Phase (planned 3 patients). Donors were consented for a second CD34+ collection to use as a rescue in the case of engraftment failure and for collection of a research blood specimen prior to mobilization.	Total n=55 Participants Total of all reporting groups
Age, Continuous	57.5 years n=5 Participants	61 years n=7 Participants	37.5 years n=5 Participants	58 years n=4 Participants
Sex: Female, Male Female	10 Participants n=5 Participants	9 Participants n=7 Participants	2 Participants n=5 Participants	21 Participants n=4 Participants
Sex: Female, Male Male	12 Participants n=5 Participants	18 Participants n=7 Participants	4 Participants n=5 Participants	34 Participants n=4 Participants
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	21 Participants n=5 Participants	27 Participants n=7 Participants	6 Participants n=5 Participants	54 Participants n=4 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Asian	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	1 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	1 Participants n=4 Participants
Race (NIH/OMB) Black or African American	2 Participants n=5 Participants	2 Participants n=7 Participants	0 Participants n=5 Participants	4 Participants n=4 Participants
Race (NIH/OMB) White	18 Participants n=5 Participants	25 Participants n=7 Participants	6 Participants n=5 Participants	49 Participants n=4 Participants
Race (NIH/OMB) More than one race	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants
Region of Enrollment United States	22 participants n=5 Participants	27 participants n=7 Participants	6 participants n=5 Participants	55 participants n=4 Participants

PRIMARY outcome

Timeframe: By day 35

Population: Donors and participants in the Expansion Phase were not evaluable for this outcome measure. There were 2 participants in the Pilot Study who were not evaluable due to not continuing with treatment due to low donor collection.

Failure to engraft will be defined as failure to achieve absolute neutrophil count \>500 for 3 days by day 35.

Outcome measures

Outcome measures
Measure	Pilot Study: Itacitinib n=20 Participants * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently * To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure.	Expansion Phase: Itacitinib * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently	Donors -Donors were consented for the patients enrolled in the Safety Lead-In Phase (planned 3 patients). Donors were consented for a second CD34+ collection to use as a rescue in the case of engraftment failure and for collection of a research blood specimen prior to mobilization.
Number of Participants With Graft Failure (Pilot Study Only)	0 Participants	—	—

PRIMARY outcome

Timeframe: Through day 100

Population: Donors were not evaluable for this outcome measure. There were 2 participants in the Pilot Study and 2 participants in the Expansion Phase who were not evaluable for this outcome measure.

-Incidence of acute grade III-IV GVHD will be assessed using Mount Sinai Acute GvHD International Consortium (MAGIC) criteria. Attempts should be made to confirm the diagnosis pathologically by biopsy of target organ(s).

Outcome measures

Outcome measures
Measure	Pilot Study: Itacitinib n=20 Participants * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently * To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure.	Expansion Phase: Itacitinib n=25 Participants * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently	Donors -Donors were consented for the patients enrolled in the Safety Lead-In Phase (planned 3 patients). Donors were consented for a second CD34+ collection to use as a rescue in the case of engraftment failure and for collection of a research blood specimen prior to mobilization.
Number of Participants With Grades III-IV Acute GVHD	0 Participants	0 Participants	—

SECONDARY outcome

Timeframe: Through day 28

Population: Donors were not evaluable for this outcome measure. There were 2 participants in the Pilot Study and 2 participants in the Expansion Phase who were not evaluable for this outcome measure.

* The number of participants who experience CRS will be summarized by count of participants who experience Grade 1, 2, 3, 4, \& 5 CRS. The worst grade experienced by participant will be noted. * Grade 1: symptoms not life threatening \& require symptomatic treatment alone, includes fever, nausea, fatigue, malaise * Grade 2: symptoms require/respond to limited intervention - oxygen (O2) \<40%, \<=3 liters (L) nasal cannula or hypotension responsive to fluids or low dose of 1 vasopressor or grade 2 renal or hepatic toxicity * Grade 3: symptoms require/respond to aggressive intervention - O2 \>=40%, \>3L nasal cannula or hypotension requiring high dose or multiple vasopressors or grade 3 renal toxicity or grade 4 transaminitis, new onset altered mental status, new cardiomyopathy without wall motion abnormality * Grade 4: life-threatening symptoms - requirement for ventilator support or grade 4 rental toxicity (excluding transaminitis) * Grade 5: death

Outcome measures

Outcome measures
Measure	Pilot Study: Itacitinib n=20 Participants * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently * To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure.	Expansion Phase: Itacitinib n=25 Participants * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently	Donors -Donors were consented for the patients enrolled in the Safety Lead-In Phase (planned 3 patients). Donors were consented for a second CD34+ collection to use as a rescue in the case of engraftment failure and for collection of a research blood specimen prior to mobilization.
Number of Participants Who Experience Cytokine Release Syndrome (CRS) Grade 1 or above	18 Participants	15 Participants	—
Number of Participants Who Experience Cytokine Release Syndrome (CRS) Grade 2 or above	5 Participants	1 Participants	—

SECONDARY outcome

Timeframe: Day 180

Population: Donors were not evaluable for this outcome measure. There were 2 participants in the Pilot Study and 2 participants in the Expansion Phase who were not evaluable for this outcome measure.

-Death that results from a transplant procedure-related complication (e.g. infection, organ failure, hemorrhage, GVHD) rather than from relapse of the underlying disease or an unrelated cause

Outcome measures

Outcome measures
Measure	Pilot Study: Itacitinib n=20 Participants * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently * To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure.	Expansion Phase: Itacitinib n=25 Participants * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently	Donors -Donors were consented for the patients enrolled in the Safety Lead-In Phase (planned 3 patients). Donors were consented for a second CD34+ collection to use as a rescue in the case of engraftment failure and for collection of a research blood specimen prior to mobilization.
Number of Participants With Treatment Related Mortality	0 Participants	0 Participants	—

SECONDARY outcome

Timeframe: Day 100

Population: Donors and participants in the Pilot Phase are not evaluable for this outcome measure. There were 2 participants in the Expansion Phase who were not evaluable for this outcome measure.

* Incidence of acute grade II-IV GVHD will be assessed using Mount Sinai Acute GvHD International Consortium (MAGIC) criteria. Attempts should be made to confirm the diagnosis pathologically by biopsy of target organ(s). * The cumulative incidence of aGVHD was estimated using Fine-Gray's sub-distribution methods to account for competing risk of death without aGVHD.

Outcome measures

Outcome measures
Measure	Pilot Study: Itacitinib * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently * To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure.	Expansion Phase: Itacitinib n=25 Participants * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently	Donors -Donors were consented for the patients enrolled in the Safety Lead-In Phase (planned 3 patients). Donors were consented for a second CD34+ collection to use as a rescue in the case of engraftment failure and for collection of a research blood specimen prior to mobilization.
Cumulative Incidence of Grades II-IV Acute GVHD (Expansion Phase)	—	20 percent Interval 7.0 to 38.0	—

Adverse Events

Pilot Study: Itacitinib

Serious events: 14 serious events

Other events: 20 other events

Deaths: 3 deaths

Expansion Phase: Itacitinib

Serious events: 24 serious events

Other events: 26 other events

Deaths: 8 deaths

Donors

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Other adverse events

Additional Information

Dr. Ramzi Abboud

Washington University School of Medicine

Phone: 314-454-8304

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place

Serious adverse events
Measure	Pilot Study: Itacitinib n=20 participants at risk * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently * To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure.	Expansion Phase: Itacitinib n=26 participants at risk * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently	Donors -Donors were consented for the patients enrolled in the Safety Lead-In Phase (planned 3 patients). Donors were consented for a second CD34+ collection to use as a rescue in the case of engraftment failure and for collection of a research blood specimen prior to mobilization.
Blood and lymphatic system disorders Anemia	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Blood and lymphatic system disorders Febrile neutropenia	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	7.7% 2/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Gastrointestinal disorders Diarrhea	15.0% 3/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Gastrointestinal disorders Enterocolitis	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Gastrointestinal disorders Nausea	10.0% 2/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	7.7% 2/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
General disorders Fever	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	15.4% 4/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations Adenovirus	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations CMV viremia	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations COVID-19 infection	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations Enterococcus bacteremia	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations Enterocolitis infectious	10.0% 2/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	11.5% 3/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations HSV stomatitis	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations Lung infection	20.0% 4/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	19.2% 5/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations MSSA bacteremia septic arthritis	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations RSV infection	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations Sepsis	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	7.7% 2/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations Skin infection	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	7.7% 2/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Metabolism and nutrition disorders Hyperkalemia	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Metabolism and nutrition disorders Hyponatremia	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Musculoskeletal and connective tissue disorders Flank pain	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Relapsed disease	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	11.5% 3/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Nervous system disorders Reversible posterior leukoencephalopathy syndrome	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Renal and urinary disorders Acute kidney injury	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	7.7% 2/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Renal and urinary disorders Cystitis noninfective	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Renal and urinary disorders Hematuria	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Renal and urinary disorders Renal colic	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Respiratory, thoracic and mediastinal disorders Dyspnea	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Respiratory, thoracic and mediastinal disorders Epistaxis	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Skin and subcutaneous tissue disorders Rash maculo-papular	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.

Other adverse events
Measure	Pilot Study: Itacitinib n=20 participants at risk * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 100. After Day 100, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 100, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 100, for patients on study drug hold, discontinue permanently * To address concerns of engraftment failure using itacitinib throughout the transplant period, for the first three patients the investigators will consent the donor for a second CD34+ collection to use as a rescue in the case of engraftment failure.	Expansion Phase: Itacitinib n=26 participants at risk * Will undergo institutionally standard myeloablative or reduced intensity chemotherapy or chemoradiotherapy * Stem cell transplantation on Day 0 * Itacitinib 200 mg/day from Day -3 to Day 180. After Day 180, for patients at a dose of 200 mg daily, reduce to 100 mg daily for 1 month, then every other day for one month, then discontinue OR after day 180, for patients already dose reduced to 100 mg daily, reduce to 100 mg every other day then discontinue OR after day 180, for patients on study drug hold, discontinue permanently	Donors -Donors were consented for the patients enrolled in the Safety Lead-In Phase (planned 3 patients). Donors were consented for a second CD34+ collection to use as a rescue in the case of engraftment failure and for collection of a research blood specimen prior to mobilization.
Blood and lymphatic system disorders Anemia	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	11.5% 3/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Blood and lymphatic system disorders Febrile neutropenia	65.0% 13/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	50.0% 13/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Cardiac disorders Supraventricular tachycardia	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Gastrointestinal disorders Colitis	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Gastrointestinal disorders Dysphagia	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Gastrointestinal disorders Esophagitis	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Gastrointestinal disorders Mucositis oral	35.0% 7/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	19.2% 5/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Gastrointestinal disorders Nausea	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Gastrointestinal disorders Rectal pain	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Immune system disorders Cytokine release syndrome	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations BK virus	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations Enterococcus faecium bacteremia	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations Enterocolitis infectious	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations Lung infection	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations Paronychia	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations Sepsis	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	7.7% 2/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Infections and infestations Urinary tract infection	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Investigations Alanine aminotransferase increased	10.0% 2/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	15.4% 4/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Investigations Alkaline phosphatase increased	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	7.7% 2/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Investigations Aspartate aminotransferase increased	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	11.5% 3/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Investigations Creatinine increased	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Investigations Electrocardiogram QT corrected interval prolonged	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	7.7% 2/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Investigations Lymphocyte count decreased	10.0% 2/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	50.0% 13/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Investigations Neutrophil count decreased	95.0% 19/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	69.2% 18/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Investigations Platelet count decreased	95.0% 19/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	61.5% 16/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Investigations Weight loss	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	7.7% 2/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Investigations White blood cell decreased	100.0% 20/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	65.4% 17/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Metabolism and nutrition disorders Anorexia	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Metabolism and nutrition disorders Hyperglycemia	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Metabolism and nutrition disorders Hypernatremia	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Metabolism and nutrition disorders Hyperphosphatemia	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Metabolism and nutrition disorders Hypertriglyceridemia	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	19.2% 5/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Metabolism and nutrition disorders Hypocalcemia	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Metabolism and nutrition disorders Hypokalemia	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	7.7% 2/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Metabolism and nutrition disorders Hypomagnesemia	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	7.7% 2/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Metabolism and nutrition disorders Hyponatremia	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Musculoskeletal and connective tissue disorders Generalized muscle weakness	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Nervous system disorders Encephalopathy	0.00% 0/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Nervous system disorders Headache	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	3.8% 1/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.
Nervous system disorders Tremor	5.0% 1/20 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	0.00% 0/26 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.	— 0/0 • - Adverse events (AEs) were tracked from start of itacitinib through 30 days after last dose (median length of follow-up 166 days, full range 16-287 days). - All-cause mortality was collected from start of itacitinib through completion of follow-up (up to day 365). * SAEs, AEs and all-cause mortality were not collected on donors. * The protocol contains the selected AEs that were collected for those in the pilot and expansion phase. * SAEs and AEs were collected on any patient who received at least one dose of itacitinib. * All-cause morality was collected for any patient who completed were compliant with the assigned treatment.